Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1997-05-06
1999-12-14
Caputa, Anthony C.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
536 235, C07K 14705, C07H 2104, C12P 1511
Patent
active
060019700
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Neuropeptide Y (NPY) is a 36 residue, amidated peptide. It is anatomically co-distributed and co-released with norepinephrine in and from sympathetic postganglionic neurons ([1], [2], [3], [4], [5], [6]). Stimulation of the sympathetic nervous system under physiological circumstances such as exercise ([7], [8]) or exposure to the cold ([9], [10]) promotes an elevation of both norepinephrine and NPY.
NPY is believed to act in the regulation of appetite control ([11], [12]) and vascular smooth muscle tone ([13], [14]) as well as regulation of blood pressure ([6], [15], [16], [17]). NPY also decreases cardiac contractility ([18], [19], [20], [21], [22]). Congestive heart failure and cardiogenic shock are associated with probable releases of NPY into the blood ([23], [24], [25]). Regulation of NPY levels may be beneficial to these disease states [26].
At the cellular level, neuropeptide Y binds to a G-protein coupled receptor ([27], [28], [29], [30]). Neuropeptide Y is involved in regulating eating behavior and is an extremely potent orixigenic agent ([11], [12], [31]). When administered intracerebroventricularly or injected into the hypothalamic paraventricular nucleus (PVN) it elicits eating in satiated rats ([32], [33], [34]) and intraventricular injection of antisera to NPY decreases eating ([11], [31]). It has been shown to stimulate appetite in a variety of species and at different stages of development ([12]). Other effects on energy metabolism include decreased thermogenesis, body temperature and uncoupling protein, and increased white fat storage and lipoprotein lipase activity ([9], [35], [36], [37], [38], [39]). NPY levels in the PVN increase upon fasting ([40], [41], [42], [43], [44]), before a scheduled meal ([31], [36], [40]), and in both streptozotocin-induced and spontaneous diabetes ([36], [45], [46], [47], [48], [49]). Also, NPY levels are increased in genetically obese and hyperphagic Zucker rats ([36], [50], [51]). Thus, a specific centrally acting antagonist for the appropriate NPY receptor subtype may be therapeutically useful for treating obesity and diabetes. Other disorders which might be targeted therapeutically include anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases ([26], [52]).
At least four receptor subtypes of the NPY family have been proposed based on pharmacological and physiological properties. The Y1 receptor is stimulated by NPY or PYY (peptide YY) and appears to be the major vascular receptor ([16], [53], [54], [55]). The Y2 receptor is stimulated by C-terminal fragments of NPY or PYY and is abundantly expressed both centrally and peripherally ([55], [56], [57], [58]). A third receptor (Y3) is exclusively responsive to NPY and is likely present in adrenal medulla, heart, and brain stem ([27], [59]). In addition, other subtypes of this receptor family are known to exist, based on pharmacological and physiological characterization ([60], [61], [62], [63]). The feeding behavior is stimulated potently by NPY, NPY.sub.2-36 and the Y1 agonist [Leu31, Pro34]NPY, but is not stimulated by the Y2 agonist NPY.sub.13-36 ([11], [64], [65], [66]). This pharmacology is not characteristic of the defined Y1, Y2 or Y3 receptors and can thus be attributed to a unique receptor, termed "atypical Y1" ([11], [65], [66]), that is responsible for evoking the feeding response. In addition, data indicate the existence of additional members of this receptor family including one subtype specific for peptide PP ([62], [63]), one with affinity for short C-terminal fragments of NPY which induce hypotension when administered systemically ([15], [17], [30], [67], [68]), and one associated with binding of NPY and PYY to brain sigma and phencyclidine binding sites ([61]).
The DNA encoding the Y 1 receptor has been cloned and shown to be a G protein coupled receptor ([53], [69], [70]). G-protein coupled receptors
REFERENCES:
patent: 5264565 (1993-11-01), England et al.
patent: 5288607 (1994-02-01), Emorine et al.
patent: 5516653 (1996-05-01), Bard et al.
patent: 5545549 (1996-08-01), Gerald et al.
patent: 5571695 (1996-11-01), Selbie et al.
patent: 5589568 (1996-12-01), Higashijima et al.
patent: 5621079 (1997-04-01), Cascieri et al.
Colmers, TINS, vol. 21, p. 89, 1998.
Rudinger, In. Peptide Hormones, ed. Parsons, University Park Press, Baltimore, pp. 1-7, 1976.
Dohlman et al., Annu. Rev. Biochem., vol. 60, pp. 653-688, 1991.
Cheung et al., Febs Lett., vol. 279, pp. 277-280, 1991.
Allen, L.F. et al, "G-protein coupled recept or genes as protoocogenes: Coonsistively among mutation of the abha 18 adrenergic receptor enhances mircogenes and sumogenicity ", Proc. Natl. Acad. Sci. vol. 88, pp. 11354-11358, Dec. 1991.
Baldwin, J.M. "The probable arrangement of the helices in G protein-coupled receptors", The EMBO Journal, vol. 12, No. 4, pp. 1693-1703.
Cheung, A.H. et al. "Separation of the Structural Requirements for Agonist-Promoted Activation and Sequestration of the beta-adrenergic receptor,", Molecular Pharm. vol. 37, pp. 775-779.
Cotecchia S., et al. "Discrete Amino Acid Sequences of the alpha 1-adrenergic receptor determine the Selectivity of Coupling to Phosphoinositide Hydrolysis", The Journal of Biological Chemistry, vol. 267, No.3 pp.1633-1639.
Dixon, R. et al., "Ligand binding to the beta-adrenergic receptor involves it rhodopsin-like core", Nature, vol. 326, Mar. 5, 1987, pp. 73-77.
England, B.P., "A chimeric D2 dopamine/ml muscarinic receptor with D2 binding specificity mobilizes intracellular calcium in response to dopamine", FEBS 09352, Feb. 1991, vol. 279, No. 1, pp. 87-90.
Hausdorff, W.P. et al. "A Mutation of the Beta2-Adrenergic Receptor Impairs Agonist Activation of Adenylyl Cyclase without Affecting High Affinity Agonist Binding", vol. 265, pp. 1388-1393 1990.
Kjelsberg, M.A. et al. "Constitutive Activation of the alpha 1B-Adrenergic receptor by all Amino acid sustitutions at a single site", The Journal of Biological Chemistry, vol. 267, No. 3, pp. 1430-1433, 1992.
Kosugi, S. et al. "Mutation of Alanine 623 in the Third Cytoplasmic Loop of the Rat Tyrotropin (TSH) Receptor Results in a Loss in the Phosphoinositide but not cAMP signal induced by TSH and receptor Autoantibodies", The Journal of Biological Chemistry, vol. 267, pp. 24153-24156, 1992.
Liggett, S.B. et al. "Coupling of a Mutated Form of the Human Beta 2-Adrenergic Receptor to Gi and Gs", The Journal of Biological Chemistry, vol. 266. No. 8. pp. 4816-4821, 1991.
O'Dowd B.F. et al. "Site-directed Mutagenesis of the Cytoplasmic Domains of the Human beta 2-Adrenergic Receptor", The Journal of Biological Chemistry, vol. 263, No. 31, pp. 15985-15992. 1988.
Ohyama K. et al. "Domains for G-Protein Coupling in Angiotensin II Receptor type I: Studies by Site-Directed Mutagenesis", vol. 189, No. 2 1992, pp. 677-683.
Samama, P. et al. "A Mutation-induced Activated State of the Beta 2-Adrenergic Receptor", The Journal of Biological Chemistry, No. 7, Issue of Mar. 5. pp. 4625-4636, 1993.
Strader, C.D. et al. "Mutations that Uncouple the Beta-Adrenergic Receptor from Gs and Increase Agonist Affinity", The Journal of Biological Chemistry, vol. 262, No. 4, pp. 16439-16443, 1987.
Weiss, J. et al. "Delineation of Muscarinic Receptor Domains Conferring Selectivity of Coupling to Guanine Nucleotide-Binding Proteins and Second Messengers", Molecular Pharmacology, vol. 38, pp. 517-523.
Wong, S. et al. "Chimeric Muscarinic Cholinergic: Beta-Adrenergic Receptors that Activate Gs in Response to Muscarinic Agonists", Jour. of Biol. Chem. vol. 265, No. 11, pp. 6219-6224, 1990.
Grundemar, L., et al., Characterization of vascular neuropeptide Y receptors Br. J. Pharmacol. 1992.105 (1):pp. 45-50.
Wahlestedt, C., et al., Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides, Regul. Pept. 1986.13 (3-4):pp. 307-318.
Jorgensen et al., Structure-function studies on neuropeptide Y
Cascieri Margaret A.
MacNeil Douglas John
Strader Catherine D.
Caputa Anthony C.
Gucker Stephen
Merck & Co. Inc
Walton Kenneth R.
Winokur Melvin
LandOfFree
Modified human neuropeptide Y1 Receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified human neuropeptide Y1 Receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified human neuropeptide Y1 Receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-864621